Becotatug

• Description :

  Becotatug (JMT-101) is a humanized IgG1 antibody targeting EGFR. Becotatug can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC. Becotatug can be used for the study of EGFR-mutated advanced non-small cell lung cancer (NSCLC) [1][2].

• Product Name Alternative :

  JMT-101; MRG003 Antibody

• UNSPSC :

  12352203

• Target :

  EGFR

• Type :

  Inhibitory Antibodies

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/becotatug.html

• Purity :

  99.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Becotatug]

• Molecular Weight :

  (145.52 kDa)

• References & Citations :

  [1]Brazel D, Kroening G, Nagasaka M. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022 Nov;36 (6) :717-729.|[2]Zhang L, et al. 614MO A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study) . Annals of Oncology. 2024 Dec 1;35:S1624-5.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2648260-93-7]